AJPC Publishes First Study Under New Editor Revealing Sex Differences in Rare Cholesterol Disorder
Event summary
- The American Journal of Preventive Cardiology (AJPC) published a landmark study on sex differences in homozygous familial hypercholesterolemia (HoFH) under new Editor-in-Chief Dr. Khurram Nasir.
- The multinational study found baseline LDL-C levels were significantly higher in females than males with HoFH, a previously unreported observation.
- Treatment with evinacumab, an ANGPTL-3 inhibitor developed by Regeneron Pharmaceuticals, reduced LDL-C levels in both sexes over 24 weeks.
- An accompanying editorial called for greater inclusion of women in cardiovascular clinical trials.
The big picture
This study highlights the growing emphasis on sex-specific data in medical research, particularly in rare genetic conditions. The publication under AJPC's new leadership signals a strategic focus on inclusive, high-impact preventive cardiology science. The findings could influence both clinical practice and regulatory standards for managing HoFH.
What we're watching
- Research Impact
- How these findings will influence future clinical trials and treatment protocols for HoFH patients.
- Editorial Direction
- Whether Dr. Nasir's leadership will continue to prioritize sex-specific analyses in preventive cardiology research.
- Regulatory Influence
- The pace at which regulatory bodies may incorporate these findings into guidelines for cardiovascular disease management.
